Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Unknown unknown|
|Therapy||Ipilimumab + Sargramostim + UV1 Telomerase peptide vaccine|
|Response Type||not applicable|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Ipilimumab + Sargramostim + UV1 Telomerase peptide vaccine||Phase I||Actionable||In a Phase I/IIa trial, UV1 Telomerase peptide vaccine combined with Yervoy (ipilimumab) and Sargramostim was well-tolerated, and resulted in a complete response and three partial responses (n=12) in metastatic melanoma patients, with a three-year overall survival of 67% (Journal of Clinical Oncology 2020 38:5_suppl, 62-62; NCT02275416).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update.||Full reference...|